D. E. Shaw & Co. Inc. Purchases 24,485 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

D. E. Shaw & Co. Inc. raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 286,079 shares of the biopharmaceutical company's stock after purchasing an additional 24,485 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.31% of Ultragenyx Pharmaceutical worth $12,035,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $35,000. Human Investing LLC bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $42,000. Van ECK Associates Corp lifted its position in shares of Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $84,000. Institutional investors own 97.67% of the company's stock.

Insider Activity

In other news, CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $3,091,571.40. Following the completion of the sale, the chief executive officer now owns 641,731 shares of the company's stock, valued at approximately $27,016,875.10. This represents a 10.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at $11,166,519.80. The trade was a 2.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 125,405 shares of company stock worth $5,285,169 over the last ninety days. Insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RARE. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Piper Sandler cut their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. JPMorgan Chase & Co. raised their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $90.93.

Ultragenyx Pharmaceutical Trading Down 1.0%

NASDAQ:RARE traded down $0.34 during mid-day trading on Monday, hitting $35.27. The company's stock had a trading volume of 128,935 shares, compared to its average volume of 823,554. The stock has a fifty day moving average of $36.39 and a 200-day moving average of $41.64. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of -5.55 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the firm posted ($2.03) EPS. Ultragenyx Pharmaceutical's revenue was up 28.0% on a year-over-year basis. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.